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Abstract
Background: GPR30 is a cell surface estrogen receptor that has been shown to mediate a number of non-genomic rapid 
effects of estrogen and appear to balance the signaling of estrogen and growth factors. In addition, progestins appear to use 
GPR30 for their actions. Therefore, GPR30 could play a critical role in hormonal regulation of breast epithelial cell integ-
rity. Deregulation of the events mediated by GPR30 could contribute to tumorigenesis.
Methods: To understand the role of GPR30 in the deregulation of estrogen signaling processes during breast carcinogen-
esis, we have undertaken this study to investigate its expression at mRNA levels in tumor tissues and their matched normal 
tissues. We compared its expression at mRNA levels by RT quantitative real-time PCR relative to GAPDH in ERα”—positive 
(n = 54) and ERα”—negative (n = 45) breast cancer tissues to their matched normal tissues.
Results: We report here, for the ﬁ  rst time, that GPR30 mRNA levels were signiﬁ  cantly down-regulated in cancer tissues in 
comparison with their matched normal tissues (p  0.0001 by two sided paired t-test). The GPR30 expression levels were 
signiﬁ  cantly lower in tumor tissues from patients (n = 29) who had lymph node metastasis in comparison with tumors from 
patients (n = 53) who were negative for lymph node metastasis (two sample t-test, p  0.02), but no association was found 
with ERα, PR and other tumor characteristics.
Conclusions: Down-regulation of GPR30 could contribute to breast tumorigenesis and lymph node metastasis.
Keywords: breast tumorigenesis, estrogen signaling, G protein coupled receptor 30 (GPR30), cell surface estrogen receptor 
and lymph node metastasis
Introduction
It is now well accepted that unopposed stimulation of breast epithelial cells by the natural hormone, 
estrogen, plays a major role in the genesis and progression of majority of breast cancers. Although the 
exact molecular mechanism(s) by which estrogen promotes breast cancer progression are not known, 
it is presumed to be through deregulation of the complex networks of processes linked to estrogen 
signaling. In the normal breast epithelial cells estrogen has been linked to gene transcription through 
two structurally related, but distinct, high afﬁ  nity receptors, ERα” and ERβ. However, ERα” seems to 
play insigniﬁ  cant role in the mature adult breast because ERα” protein is expressed only in a small 
fraction of normal epithelial cells. ERβ presumably plays an important role in maintaining homeostasis 
in breast because it is expressed in all the epithelial cells. It has become increasingly clear in recent 
years that a third molecule, a cell surface protein, G protein coupled receptor 30 (GPR30), mediates a 
number of rapid, non-genomic estrogen signaling processes and presumably contributes in maintaining 
the functional integrity of breast epithelial cells (1, 2).
In an effort to understand the complexity of deregulated cellular processes linked to estrogen signal-
ing during breast carcinogenesis, we have been studying the expression of estrogen receptors in cancer 66
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tissues in comparison with normal breast tissues. 
We and others have shown that ERβ mRNA and 
protein levels were markedly diminished during 
breast carcinogenesis (3–5). A number of research-
ers have established that a majority (~70%) of 
breast cancers have up-regulation of ERα” expres-
sion (5). We have undertaken the current study to 
understand the role of the third receptor, the cell 
surface estrogen receptor, GPR30, expression in 
breast tumorigenesis. We report here that it is mark-
edly down regulated during breast carcinogenesis, 
similar to ERβ.
Materials and Methods
HotStartTaq PCR core kits and Omniscript reverse 
transcriptase kits were from QIAGEN Inc. TaqMan 
Universal PCR Master Mix, RNAse inhibitor, 
random hexamers and GPR30 speciﬁ  c gene expres-
sion Assays-on-demand reagent (TaqMan® Gene 
Expression Assay ID Hs00173506_m1) were from 
Applied Bio-systems Inc.
Breast tumor samples 
and their matched normal tissues
Breast tumor tissues and their matched normal 
tissues were collected from Howard University 
Hospital immediately after surgery and stored at 
−80 ºC until use. Tumor samples for research were 
routinely harvested immediately adjacent to the 
histological/diagnostic section and were consid-
ered representative of the tissues used for diagno-
sis. Matched normal tissues were collected from 
a region distant from the tumor tissue of the same 
patient. All normal tissues used were examined by 
the participating pathologist and were proven to 
be devoid of any tumor tissue by histological 
staining. All the tumor samples were also exam-
ined by a pathologist and tissues containing more 
than 80%–90% cancer cells were excised and used 
for research. ERα” status in the tissues collected 
was determined immunohistochemically at 
Oncotech Laboratories using monoclonal antibod-
ies against NH2-terminal portion of the molecule. 
The tumor tissues that had more than 5% positive 
cells were considered positive for ERα”. A total of 
99 (n = 54 ERα”-positive and n = 45 ERα”-negative) 
cancer tissues and their matched normal tissues 
were included in the current study. Every normal-
tumor matched pair was derived from the same 
patient. Tumor collection procedures were 
approved by the IRB at Howard University. The 
total number of grade I tumors were six, grade II 
tumors were 32, grade III tumors were 50 and the 
grade scoring for ten samples was not available. 
The total number of Stage 0 tumors were 14, 
Stage I tumors were 18, Stage II tumors were 40 
and Stage III tumors were 12 and staging informa-
tion for 15 tumors was not available. The details 
about the ERα” status, PR status, ages of the patients 
at which diagnosis were made, stage, grade, his-
tological types, lymph node metastasis and meno-
pausal status are given in Table 1.
RNA extraction and cDNA synthesis
Total RNA was extracted from frozen breast tis-
sues using Trizol reagent (Gibco-BRL Life 
Technologies) as previously described (3, 6, 7). 
RNA integrity was veriﬁ  ed by both electropho-
resis in 1.5% agarose gels and ampliﬁ  cation of 
the constitutively expressed gene, glyceralde-
hyde-3 phosphate dehydrogenase (GAPDH). The 
total RNAs were reverse transcribed using 
Omniscript reverse transcriptase as previously 
described (3, 6–8).
Conventional PCR and identiﬁ  cation 
of PCR products
GPR30 was ampliﬁ  ed by conventional PCR in 
an automatic thermal cycler (MJ Research, 
Waltham, MA) in a total volume of 12.5 µL with 
cDNA equivalent to 5 ng of reverse transcribed 
total RNA as previously described (9) using 
GPR30 speciﬁ  c sense primer, 5’ ACCAACATCT-
GGACGGCAGGTA 3’ (position, exon 1, 420–441 
bp, NCBI accession No. NM_001505) and an 
antisense primer, 5’-AAGCGTGATTCTCCTT-
GAAG-3’ (660–679 bp, NCBI accession No. 
NM_001505) (10). GAPDH was ampliﬁ  ed in 
parallel for only 30 cycles with cDNA reverse 
transcribed from 5 ng of total RNA using sense 
and anti-sense primers, 5’ AAGGCTGAGAAC-
GGGAAGCTTGTCATCAAT 3’ and 5’TTCCC-
GTCTAGCTCAGGGATGACCTTGCCC3’, as 
previously described (7). The PCR ampliﬁ  ed 
products (5.0 µL) were separated by electropho-
resis in 1% Nu Sieve gels in Tris acetic acid EDTA 
buffer and detected by ethidium bromide staining. 
The PCR ampliﬁ  ed products by GPR30 speciﬁ  c 
primers were puriﬁ  ed by extracting the gel, cloned 
into pCR2.1-TOPO vector and the identity to 
GPR30 was conﬁ  rmed by sequence analysis as 
previously described (11).67
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s Quantiﬁ  cation of GPR30 mRNA 
by quantitative real-time PCR
Quantitative Real-Time PCRs were performed in 
ABI Prism GeneAmp 7900HT Sequence Detec-
tion System at a modiﬁ  ed 50% Ramp rate as 
previously described (7, 12, 13). A typical real-
time PCR reaction mixture contained cDNA 
prepared from reverse transcription of 50 ng of 
tumor total RNA, 1 X GPR30 speciﬁ  c Assays-on- 
Demand reagent that contains tested primers and 
probe and 1 X Taqman Universal PCR mix in a 
total volume of 20 µL. The PCR conditions were 
initial hold at 50 °C for two minutes, followed by 
denaturation for ten minutes at 95
 °C, and 
denaturation for 15 seconds at 95 °C in the 
subsequent cycles and annealing and extension 
for 1.5 min at 60
 °C for 40 cycles. All the samples 
were ampliﬁ  ed in triplicate and real-time PCRs 
were repeated four times and normalized to 
the copy numbers of the housekeeping gene, 
GAPDH. Absolute quantification of GAPDH 
mRNA copy numbers was performed as previ-
ously described (12, 13). The sense, and anti-sense 
primers and probe for quantiﬁ  cation of GAPDH 
were 5’-TTCCAGGAGCGAGATCCCT-3’, 
5’GGCTGTTGTCATACTTCTTCTCATGG-3’, 
and FAM 5’-TGCTGGCGCTGAGTACGTC-
GTG-3’ TAMARA respectively.
Statistical analysis
The mRNA expression levels of GPR-30 in tumor 
tissues and their matched normal tissues were com-
pared using two-sided paired t-test. The association 
between the expression of GPR30 with clinico-
pathological parameters such as grade, stage, his-
tological type, menopausal status and progesterone 
receptor status was tested by Analysis of Variance 
(ANOVA). The association between GPR30 mRNA 
levels and ERα presence was tested using two sided 
t-test. The association between GPR30 mRNA 
levels and metastasis to lymph nodes was tested 
using two sample t-tests. Test results were consid-
ered signiﬁ  cant if P values were 0.05.
Results
To understand the role of the newly described cell 
surface estrogen-binding GPR30 in tumorigenesis, 
we studied its expression at mRNA levels by 
quantitative real-time PCR. We present here the 
results demonstrating that GPR30 expression is 
signiﬁ  cantly down-regulated in cancer tissues in 73
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comparison with their matched normal tissues. We 
also present here results demonstrating that GPR30 
expression is signiﬁ  cantly lower in tumors derived 
from patients with lymph node metastasis in 
comparison with tumors from patients with no 
lymph node metastasis. GPR30 expression levels 
do not correlate to any other clinico-pathological 
characteristics.
GPR30 expression at mRNA levels 
is signiﬁ  cantly lower in breast tumor 
tissues in comparison with their 
matched normal tissues
To understand the role of GPR30 in tumorigenesis, 
we ﬁ  rst tested its expression in tumors and their 
matched normal tissues by conventional RT PCR. 
GPR30 speciﬁ  c primers generated 260 bp PCR 
product (Fig. 1). Cloning the 260 bp product into 
pCR2.1-TOPO vector and sequence analysis 
conﬁ  rmed that it is the GPR30 speciﬁ  c sequence 
(data not shown). By RT and conventional PCR, 
we observed signiﬁ  cantly lower GPR30 mRNA 
levels in tumor tissues compared to their matched 
normal tissues and this diminished expression 
varied among tumor samples. Results from six 
matched normal-tumor pairs from each of 
ERα-positive and ERα-negative tumor groups are 
shown in Figure 1A and Figure 1B respectively.
We next quantiﬁ  ed the GPR30 mRNA levels 
relative to the GAPDH levels in normal tissues and 
their matched tumor tissues using RT quantitative 
real-time PCR and comparative delta Ct method 
(14). By using these procedures we found that 
among the ERα- positive tissues, the mean GPR30 
mRNA expression levels relative to GAPDH lev-
els were 0.0058 (SD = 0.0075) in normal tissues 
and 0.0026 (SD = 0.0038) in cancer tissues. We 
next compared the relative expression levels 
between cancer tissues and their matched normal 
tissues using two- sided paired t-test. By applying 
this test, we found that GPR30 expression levels 
in cancer tissues was signiﬁ  cantly lower than that 
in the normal tissues in a majority of cases 
(P = 0.0024; two-sided paired t-test). Among the 
ERα-negative samples, the relative mean GPR30 
expression was 0.0067 (SD = 0.0081) in normal 
tissues and 0.0025 (SD = 0.0050) in cancer tissues. 
We observed a large standard deviation presumably 
because of very high variation in the individual 
tissues. The expression levels of GPR30 were also 
found to be signiﬁ  cantly different between normal 
and ERα-negative cancer tissues (P  0.0007; 
two-sided paired t-test). A statistically signiﬁ  cant 
difference between normal and cancer tissues 
remains when all ERα-positive and ERα-negative 
tissues were combined (P  0.0001; two-sided 
paired t-test). However, no signiﬁ  cant difference 
was found in either normal or cancer tissue samples 
when we compared GPR30 mRNA levels between 
ERα-positive and ERα-negative tissues. (P = 0.5570 
for normal samples, and P = 0.8980 for cancer 
samples by two-sided t-test). Quantitative data 
from 99 normal-tumor pairs are presented in Table 1. 
The mean expression values in each stage group 
in both ERα-positive and ERα-negative groups 
are shown in Table 2. Tracings of the ampliﬁ  cation 
plots by Q real-time PCR for matched normal-
tumor pairs two each from ERα-positive and 
ERα-negative groups are shown in Figure 2. 
The bar graphs showing the mean expression levels 
in tumors and normal tissues by Q real-time PCR 
are presented in Figure 3.
The GPR30 mRNA levels were 
inversely correlated to lymph node 
metastasis but not to other clinico-
pathological characteristics
After establishing that GPR30 levels were signiﬁ  -
cantly lower in cancer tissues compared to their 
matched normal tissues, we next tested whether 
any correlation exists between its levels and 
clinico-pathological characteristics by analysis of 
variance (ANOVA). When we compared the 
GPR30 values between three tumor grades the 
mean values obtained for Grade I, Grade II and 
Grade III were 0.0040, 0.0029 and =0.0023 respec-
tively. By ANOVA we did not ﬁ  nd any statistically 
signiﬁ  cant difference in GPR30 levels among the 
cancer tissues of different grades (P-values for 
testing null hypothesis (H0): g1 = g2, g2 = g3, g3 = g1 
were 0.6046, 0.5966, and 0.4182 respectively). 
Similarly, the mean expression values for Stage 0, 
I, II and III were 0.0033, 0.0047, 0.0018 and 
0.0013, respectively, and no statistically signiﬁ  cant 
differences were found among samples of different 
stages by ANOVA (P-values for testing H0: t1 = t2, 
t1 = t3, t1 = t4, t2 = t3, t2 = t4, t3 = t4 were 0.3677, 
0.3029, 0.2717, 0.0258, 0.0452, and 0.7314 respec-
tively). We also did not find any association 
between GPR30 levels with menopausal status, 
progesterone status, ages of the patients at 
diagnosis, ERα, or histological type of the tumor. 74
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However, we found a signiﬁ  cant association with 
tumor metastasis to lymph nodes. The cancer tis-
sues from patients who were negative for lymph 
node metastasis (n = 53) had signiﬁ  cantly higher 
expression (mean = 0.0033, SD = 0.0055) than 
tumors from patients who were positive for lymph 
node metastasis (n = 29) (mean = 0.0014, SD = 
0.0016) (Table 3). Again, we observed a large 
standard deviation presumably due to very high 
variation in individual samples. The P-value by a 
two-sample t-test was 0.02. Bar graphs showing 
the mean expression levels in tumors from patients 
who were positive and negative for lymph node 
metastasis are presented in Figure 4.
Discussion
For several years there has been a speculation that 
estrogen could be binding to a cell surface membrane 
protein independent of ERα and ERβ (15, 16). In 
recent years several independent research teams 
have identiﬁ  ed GPR30 as the membrane protein that 
binds estrogen (17–19). GPR30 belongs to the super 
family of over 1000 of seven-transmembrane span-
ning cell surface orphan receptors that are known 
to bind agonists such as chemokines, vasoreactive 
substances and neurotransmitters (20).
It is now fairly well recognized that GPR30 
binds estrogen and the complex is internalized to 
trigger a variety of rapid non-genomic estrogen 
signaling events that include increasing the second 
messenger levels such as Ca
+ mobilization (21), 
NO generation (22), intracellular phosphatidyl 
inositol 3, 4, 5 triphosphates (23), cAMP (24) and 
activation of MAP kinases, Erk1 and Erk2 (25). 
Data are emerging on the details about the non-
genomic actions of estrogen on cellular events and 
cross-talk with growth factor mediated Erk1 and 
Figure 1. The cell surface estrogen receptor, GPR30, mRNA expression levels were decreased signiﬁ  cantly in tumor tissues in comparison 
with their matched normal tissues. The tissue cDNAs were ampliﬁ  ed for GPR30 by conventional PCR as described in Materials and Methods. 
Examples from six matched normal-tumor pairs in ERα-positive (A) and ERα-negative (B) tumor groups are shown. Relative levels of the 
house keeping gene, GAPDH, are also shown.75
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Erk2 activation through release of cell surface 
associated EGF and activation of EGFR tyrosine 
kinase activity (26). It appears that through GPR30, 
estrogen triggers opposing G protein dependent 
signaling mechanisms that act to balance MAPK 
signaling cascade events, Erk1 and Erk2 activation 
(27). Since a number of growth signaling molecules 
use MAPK cascade and cross-talk with ERα to 
increase cell proliferation, the dual regulation of 
Erk1/2 activation by GPR30 suggests that a 
coordinated signaling between GPR30 and ERα 
is required for controlled growth and regulation of 
normal epithelial cells. In addition to estrogen, the 
proliferation opposing progestins also seem to use 
GPR30 for their actions (28). It has been reported 
that continuous administration of progestins inhibit 
breast cancer cell proliferation and GPR30 is 
critical for this growth inhibition (29). All these 
reports suggest that GPR30 could play a critical 
role in hormonal regulation of breast epithelial cell 
integrity. Deregulation of the events mediated by 
GPR30 could contribute to tumorigenesis and 
inﬂ  uence clinicopathological behavior of breast 
cancer.
As a ﬁ  rst step in understanding the role of 
GPR30 in the deregulation of estrogen signaling 
processes during breast carcinogenesis, we have 
undertaken this study to investigate its expression 
at mRNA levels in tumor tissues and their matched 
normal tissues. Previously, GPR30 expression was 
investigated by Weigel’s group (10) at mRNA 
levels in seven ERα-negative and four ERα-
positive breast cancer tissue by conventional RT 
PCR. They reported the presence of GPR30 mRNA 
in one ERα-positive and all four ERα-negative 
breast cancer tissues. However, there were no data 
on its expression in normal breast tissues and the 
number of tissues analyzed was too small to draw 
statistically signiﬁ  cant conclusions. Ravanakar 
et al. (17) reported GPR30 expression in breast 
cancer cell lines. Filardo et al. studied the expres-
sion of GPR30 protein levels in 12 reduction 
mammoplasty and 361 breast cancer tissues by 
immunohistochemistry. They reported its presence 
in all reduction mammoplasty and 62% of cancer 
tissues and an association with ERα, Her2/neu and 
tumor size and inverse correlation with metastasis. 
However, their study did not establish its role in 
breast tumorigenesis because their control (normal) 
tissue samples were very few, not matched with 
the tumor samples, and the assay employed was 
not quantitative (30).
In the current study, to understand the role of 
GPR30 in tumorigenesis, we studied its expression 
Table 2. Summary of the specimens used and the mean GPR30 expression values.
ERα Status of 
tumors
# of specimens 
studied
Mean (SD) of GPR30 
Expression level 
(relative to GAPDH) 
in cancer tissues
Mean (SD) of GPR30 
Expression level 
(relative to GAPDH) 
in normal tissues
ERα-positive 54 0.0026 (0.0038) 0.0058 (0.0075)
Stage 0 13 0.0033 (0.0038) 0.0067 (0.0079)
Stage I 5 0.0055 (0.0088) 0.0057 (0.0084)
Stage II 24 0.0017 (0.0016) 0.0056 (0.0083)
Stage III 6 0.0018 (0.0024) 0.0057 (0.0054)
Stage IV 0 0 0
Stage 6 0.0028 (0.0048) 0.0050 (0.0061)
Not available
ERα-negative 45 0.0025 (0.0050) 0.0067 (0.0081)
Stage 0 1 0.0026 (NA) 0.0051 (NA)
Stage I 13 0.0044 (0.0090) 0.0060 (0.0065)
Stage II 16 0.0020 (0.0017) 0.0095 (0.0111)
Stage III 6 0.0008 (0.0007) 0.0025 (0.0021)
Stage IV 0 0 0
Stage 9 0.0016 (0.0014) 0.0059 (0.0056)
Not available76
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in matched normal-tumor tissue pairs, each pair 
derived from the same patient. We employed a 
quantitative approach to determine the levels of 
GPR30 mRNA by RT quantitative real-time PCR 
with reference to the levels of a house keeping gene, 
GAPDH. The data presented here on 99 matched 
normal-tumor pairs demonstrate that GPR30 gene 
expression is markedly down regulated in cancer 
tissues in comparison with their matched normal 
tissues. We observed diminished expression of 
GPR30 mRNA in most of the cancer tissues in 
comparison with their respective matched normal 
tissues (n = 99, p  0.0001 by two sided paired t-
test). Our results suggest that tumorigenesis may 
arise, in part, by the loss of GPR30. However, Mag-
giolini et al. have shown that GPR30 activation in 
breast, ovarian and endometrial cancer cell lines 
triggers signaling pathways such as MAPK pathway 
involved in cell proliferation (31, 32, 33). Perhaps, 
the opposing effects of GPR30 on the EGF-receptor 
mediated MAPK pathway may explain its role both 
Figure 2. Tracings of ampliﬁ  cation plots by RT Q real-time PCR showing expression of GPR30 in normal—tumor pairs. The RT Q real-time 
PCR for GPR30 was conducted as described in Materials and Methods. The mRNA expression levels were decreased signiﬁ  cantly in tumor 
tissues (T) in comparison with their matched normal tissues (N). Examples of ampliﬁ  cation plots for two matched normal-tumor pairs in 
ERα-positive and ERα-negative tumor groups are shown.
Figure 3. The mean expression levels of GPR30 relative to GAPDH 
in ERα positive and negative tumor (T) tissues and the normal (N) 
tissues are shown. The GPR30 levels were signiﬁ  cantly lower in 
tumor tissues in comparison with their matched normal tissues 
(P = 0.0024 for ERα positive tissues and P  0.0007 for ERα negative 
tissues, both by two-sided paired t-test). Height of the box represents 
the mean and height of the bar represents standard deviation above 
the mean.
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in transformation and inhibition as demonstrated by 
Filardo et al. (34).
Although the decrease was observed in a major-
ity of tissue pairs, it varied from one matched pair 
to the other (Table 1 and Table 2) and the variation 
did not correlate to tumor size, grade, stage, age at 
diagnosis, menopausal status, and histological 
type. The down-regulation of GPR30 during breast 
carcinogenesis also appears to be independent of 
ERα protein expression (P = 0.898, by two sided 
t-test, n = 54 ERα”—positive and n = 45 ERα”—
negative). The decreased levels of GPR30 during 
breast carcinogenesis, independent of ERα and 
other clinicopathological characteristics of tumors, 
are similar to ERβ expression. We and several other 
researchers have reported lack of association of 
ERβ levels with tumor characteristics and ERα 
expression (7,35–36).
Although the variation of decreased GPR30 
expression did not correlate to tumor size, ERα, 
grade, stage, menopausal state, age and histo-
logical type, we observed a much marked 
decreased expression in tumor tissues from 
patients who were positive for lymph node 
metastasis compared to the tumor tissues from 
patients who were negative for lymph node 
metastasis (Table 1, Table 3 and Fig. 4) (Two 
sample t-test, P  0.02, n = 29 node positive and 
n = 53 node negative). Our results on inverse 
correlation of GPR30 expression with lymph 
node metastasis are in agreement with the report 
by Filardo et al. (30). Because of the inverse 
association with lymph node metastasis, the 
relative levels of GPR30 to GAPDH could be 
applied as a marker to determine the cancer cell 
invasion.
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